Immunoreactivity for fascin, an actin-bundling protein related to cell motility, has been reported in breast, ovary, pancreas, skin, and @entity4153 , and associated with more @entity1442 stage and poorer prognosis. Data on pulmonary neuroendocrine (NE) @entity5 , however, are lacking. We evaluated the expression of fascin by immunohistochemistry--using two different monoclonal antibodies--in surgical specimens of @entity2 of all the diverse histological types from 128 consecutive @entity1 recruited between 1987 and 2001, and investigated its relationship with the presence of lymph node @entity3 . Overall, fascin immunoreactivity was detected in 5% of 38 typical @entity4303 (TC), 35% of 23 @entity4303 ( @entity4303 ), 83% of 40 @entity152 ( @entity152 ), and 100% of 27 @entity151 ( @entity151 ) (P<0.001), Normal NE cells or hyperplastic NE tumorlets were consistently unreactive. No statistically significant differences in fascin immunoreactivity were found between the two antibodies. In TC and @entity4303 but not high-grade NE @entity5 , fascin immunoreactivity closely correlated with the occurrence of lymph node @entity3 , the pN class and the number of involved lymph nodes (P<0.001). It was also significantly associated with an increased proliferative activity (Ki-67 labeling index >5%) (P=0.020), and with either down-regulation or altered subcellular compartmentalization of @entity5962 (P<0.001) and @entity3778 (P=0.030), two cell adhesion complexes in @entity2 . At multivariate analysis, only fascin emerged as an independent predictor of lymph node @entity3 in this @entity5 group (HR 30.28; 95% confidence intervals: 1.59-574.49; P=0.023). This study indicates that fascin immunoreactivity may identify subsets of @entity358 @entity1 with different metastatic potential to regional lymph nodes. Targeting the fascin pathway could be a novel therapeutic strategy of @entity358 .

Independent value of fascin immunoreactivity for predicting lymph node @entity3 in typical and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4153 :: ('MESH:D018288', 'Disease') :: ['non-small cell carcinomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity2 :: ('MESH:D008175', 'Disease') :: ['pulmonary NE tumors'] @entity5962 :: ('999', 'Gene') :: ['E-cadherin'] @entity3778 :: ('4267', 'Gene') :: ['CD99'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary carcinoids', 'pulmonary carcinoid'] @entity152 :: ('MESH:D018287', 'Disease') :: ['LCNEC', 'large-cell neuroendocrine carcinomas'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity4303 :: ('MESH:D002276', 'Disease') :: ['atypical carcinoids', 'AC', 'carcinoids'] @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC', 'small-cell lung carcinomas']
@entity358 :: (MESH:D008171,Disease) :: ['atypical pulmonary carcinoids']
